Direkt zum Inhalt
Merck
  • The control of alternative splicing by SRSF1 in myelinated afferents contributes to the development of neuropathic pain.

The control of alternative splicing by SRSF1 in myelinated afferents contributes to the development of neuropathic pain.

Neurobiology of disease (2016-10-19)
Richard P Hulse, Robert A R Drake, David O Bates, Lucy F Donaldson
ZUSAMMENFASSUNG

Neuropathic pain results from neuroplasticity in nociceptive neuronal networks. Here we demonstrate that control of alternative pre-mRNA splicing, through the splice factor serine-arginine splice factor 1 (SRSF1), is integral to the processing of nociceptive information in the spinal cord. Neuropathic pain develops following a partial saphenous nerve ligation injury, at which time SRSF1 is activated in damaged myelinated primary afferent neurons, with minimal found in small diameter (IB

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Monoklonaler Anti-Neurofilament-200-Antikörper (phos. und nicht-phos.) in Maus hergestellte Antikörper, clone N52, ascites fluid
Preise und Verfügbarkeit sind derzeit nicht verfügbar.
Sigma-Aldrich
SRPIN340, ≥98% (HPLC)
Preise und Verfügbarkeit sind derzeit nicht verfügbar.